Expertise in
gene writing

Integra Therapeutics is a biotech company that is creating next-generation gene writing tools to boost the efficiency and safety of advanced therapies.

Advanced therapies are a pillar of the medicine of the future.

Our lead technology is FiCAT, a best-in-class platform geared towards resolving the current limitations on gene writing: size, precision and stability. It is based on research from the laboratory of Dr Marc Güell at Pompeu Fabra University.

We are a multidisciplinary team of researchers in biology, molecular biology and genetics, biomedical engineers, and business development and communications professionals who are passionate and committed to moving FiCAT technology forward, bringing it to patients who urgently need it. We also have the support of our investors and board of directors, who are industry leaders with strong track records in drug development.


Transfer our scientific knowledge and technological skills to the biopharmaceutical industry to cure genetic and oncological diseases with high unmet medical need.


Marc Güell, PhD

PhD in Biomedicine from UPF and degree in Chemical and Telecommunications engineering from IQS. After doing his doctorate research at the European Molecular Biology Laboratory (EMBL) and the Centre for Genomic Regulation (CRG), in 2011 he joined the Harvard University Wyss Institute, led by Professor George Church, a pioneer in genome sequencing and gene editing. In 2017, he returned to Barcelona to join the UPF as a tenure-track professor in the Department of Experimental and Health Sciences and to lead the Translational Synthetic Biology Lab. In 2022, he has won the National Research Award for Young People awarded by the Ministry of Science and Innovation in Spain and he has been made a member of the Young Academy of Spain (AJE). He is the author of articles with more than 11,000 citations and patents that have been the basis of three biotechnology companies: Integra Therapeutics, eGenesis and S-Biomedic.

Avencia Sánchez-Mejías, PhD

PhD in Molecular Biology and Master in Biomedical Research from the University of Seville. She has had a solid career in clinical genetics, molecular oncology and synthetic biology in several countries. She did her PhD at the Institute of Biomedicine of Seville and post-doc at the National University of Singapore and University of Miami Miller School of Medicine. In 2018, she joined the Translational Synthetic Biology Lab at UPF. In recent years, she has focused on transferring the knowledge generated in the institution to society through her entrepreneurial project, Integra Therapeutics. She is committed to helping develop female talent and encouraging coming generations to go into STEM fields. In 2022, she received Women and Leadership Award promoted by Deusto Business School, Cinco Días and Banco Santander.